Cellectar Biosciences, Inc.
CLRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $13,778 | $53,797 | $15,913 | $36,640 |
| - Cash | $23,289 | $9,565 | $19,866 | $35,704 |
| + Debt | $494 | $553 | $604 | $302 |
| Enterprise Value | -$9,017 | $44,785 | -$3,349 | $1,238 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$51,486 | -$38,768 | -$28,665 | -$23,981 |
| % Margin | – | – | – | – |
| Net Income | -$44,581 | -$42,771 | -$31,793 | -$24,122 |
| % Margin | – | – | – | – |
| EPS Diluted | -41.89 | -104.988 | -135.179 | -130.353 |
| % Growth | 60.1% | 22.3% | -3.7% | – |
| Operating Cash Flow | -$47,583 | -$32,377 | -$25,222 | -$22,569 |
| Capital Expenditures | -$104 | -$864 | -$226 | -$141 |
| Free Cash Flow | -$47,687 | -$33,241 | -$25,448 | -$22,710 |